Trial Profile
Effects of Pentoxiphylline on Left Ventricular Systolic Function Indices and Circulating Biomarkers in Patients With Chronic Congestive Heart Failure.
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase II
Latest Information Update: 04 Aug 2022
Price :
$35
*
At a glance
- Drugs Pentoxifylline (Primary)
- Indications Heart failure
- Focus Biomarker; Therapeutic Use
- Acronyms PENT-CHF
- 28 Jul 2022 Status changed from discontinued to withdrawn prior to enrolment.
- 14 Feb 2022 Status changed from recruiting to discontinued.
- 28 Aug 2013 Planned end date changed from 1 Jul 2012 to 1 Jul 2014 as reported by ClinicalTrials.gov.